Impact of ABCB1 and CYP2D6 polymorphisms on tamoxifen treatment outcomes and adverse events in breast cancer patients.

CONCLUSIONS: Although no conclusive statistical association between the examined polymorphisms and the outcome or incidence of AEs in tamoxifen therapy was found, the impact of ABCB1 polymorphisms warrants further research. The importance of finding predictive pharmacogenomic biomarkers is a major challenge for individualization and pharmaco-economic rationalization of therapy. The latest international guidelines support this notion. PMID: 29135105 [PubMed - in process]
Source: Journal of B.U.ON. - Category: Cancer & Oncology Tags: J BUON Source Type: research